Sonnet BioTherapeutics (SONN) News Today → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free SONN Stock Alerts $1.74 -0.11 (-5.69%) (As of 10:59 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)markets.businessinsider.com - April 17 at 12:52 AMShort Interest in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Declines By 18.9%americanbankingnews.com - April 15 at 5:40 AMAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)markets.businessinsider.com - April 12 at 12:34 PMSonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objectivefinance.yahoo.com - March 11 at 8:20 AMSonnet BioTherapeutics Holdings Inc Ordinary Shares SONNmorningstar.com - March 1 at 12:26 AMSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteersfinanznachrichten.de - February 29 at 7:25 PMSonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose Escalationmsn.com - February 29 at 7:25 PMSonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats Expectationsfinance.yahoo.com - February 17 at 9:28 AMSonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Updatefinance.yahoo.com - February 14 at 10:41 AMNasdaq panel expected to decide on Yield10 listing within next monthmsn.com - February 7 at 9:08 PMBTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)markets.businessinsider.com - January 1 at 8:32 AMSonnet BioTherapeutics files for $100M mixed shelfmsn.com - December 22 at 8:14 PMSonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapyfinance.yahoo.com - December 21 at 11:12 AMBuy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial Fortitudemarkets.businessinsider.com - December 16 at 10:11 AMSonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Updatefinance.yahoo.com - December 14 at 7:38 PMSonnet BioTherapeutics Provides Fiscal Year 2023 Business Overviewfinance.yahoo.com - October 31 at 8:51 AMWhat's Happening With Sonnet BioTherapeutics (SONN) Shares?benzinga.com - October 26 at 3:19 PMDow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Resultsmarkets.businessinsider.com - October 25 at 4:02 PMSonnet BioTherapeutics down 32%, prices $4.55M stock offeringmsn.com - October 25 at 4:02 PMWhy Sonnet BioTherapeutics (SONN) Stock Is Getting Hammeredbenzinga.com - October 25 at 4:02 PMSonnet BioTherapeutics Shares Slide Premarket After Stock Offeringmarketwatch.com - October 25 at 9:30 AMWhy Is Sonnet BioTherapeutics (SONN) Stock Down 33% Today?msn.com - October 25 at 9:30 AMSonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offeringfinance.yahoo.com - October 25 at 9:30 AMSonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meetingfinance.yahoo.com - October 17 at 1:15 PMAnalysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Aldeyra Therapeutics (ALDX)markets.businessinsider.com - October 17 at 8:14 AMSonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technologyfinance.yahoo.com - September 20 at 10:10 AMSonnet BioTherapeutics regains listing compliancemsn.com - September 19 at 1:35 PMSonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliancefinance.yahoo.com - September 19 at 1:35 PMmarketbeat.com - September 1 at 10:07 AMmarketbeat.com - September 1 at 9:40 AMSonnet BioTherapeutics launches 1-for-22 reverse stock splitmsn.com - August 31 at 8:10 PMWhy Sonnet BioTherapeutics Stock (SONN) Is Getting Obliteratedbenzinga.com - August 31 at 8:10 PMSonnet BioTherapeutics Announces 1-for-22 Reverse Stock Splitfinance.yahoo.com - August 31 at 8:10 PMChardan Capital Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)markets.businessinsider.com - August 17 at 7:05 AMSonnet BioTherapeutics Shares Rise After FDA Approves Drug Trialmarketwatch.com - August 16 at 4:04 PMSonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the USfinance.yahoo.com - August 16 at 9:50 AMSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Updatefinanznachrichten.de - August 14 at 9:19 AMSonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Updatefinance.yahoo.com - August 14 at 9:19 AMWhy Is Sonnet BioTherapeutics (SONN) Stock Down 5% Today?investorplace.com - July 31 at 12:06 PMSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conferencefinanznachrichten.de - July 31 at 9:32 AMSonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conferencefinance.yahoo.com - July 31 at 9:32 AMBeat the Market the Zacks Way: Vertiv, Costco, Sonnet BioTherapeutics in Focusfinance.yahoo.com - July 3 at 8:29 AMSonnet BioTherapeutics stock plummets 20% on $2.25M registered direct offeringseekingalpha.com - June 29 at 8:57 AMWhy Sonnet BioTherapeutics (SONN) Stock Is Nosedivingmsn.com - June 28 at 2:07 PMSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placementfinanznachrichten.de - June 28 at 8:51 AMSonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placementfinance.yahoo.com - June 28 at 8:51 AMSonnet BioTherapeutics Holdings (SONN) Receives a Buy from EF Huttonmarkets.businessinsider.com - June 26 at 1:55 PMSonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathyfinance.yahoo.com - June 23 at 1:03 PMSonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumabfinance.yahoo.com - June 20 at 10:07 AMAnalysts Offer Insights on Healthcare Companies: SAB Biotherapeutics (SABS) and Geron (GERN)markets.businessinsider.com - June 15 at 9:15 AM Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address See this before next week's Fed meeting (Ad)See this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) Click here to see it. SONN Media Mentions By Week SONN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SONN News Sentiment▼0.000.44▲Average Medical News Sentiment SONN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SONN Articles This Week▼01▲SONN Articles Average Week Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: China Pharma News Today GT Biopharma News Today LumiraDx News Today Synaptogenix News Today Bright Minds Biosciences News Today Kineta News Today Seelos Therapeutics News Today Soligenix News Today Alzamend Neuro News Today PaxMedica News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SONN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin AnalyticsYour Money is Not SafeAmerican Alternativetop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
